NCT07276425

Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis

Early and Long-term Clinical Efficacy and Local Tissue and Peripheral Immune Changes Following Dupilumab Treatment in Prurigo Nodularis Patients

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 40 (estimated)
• Sponsor: UMC Utrecht · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.

Conditions

• Prurigo Nodularis (PN)

Interventions

Type	Name	Description
DRUG	Dupilumab	In the Netherlands, the standard care for patients with moderate-to-severe prurigo nodularis who have failed or are contraindicated to conventional systemic immunosuppressive treatments consists of 300 mg of dupilumab administered subcutaneously every two weeks, following a loading dose of 600 mg administered subcutaneously.

Timeline

• Start date: 2025-06-01
• Primary completion: 2028-06-01
• Completion: 2028-06-01
• First posted: 2025-12-11
• Last updated: 2025-12-18

Locations

1 site across 1 country: Netherlands